Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Phase 3 first-line durvalumab with or without tremelimumab plus platinum-etoposide versus platinum-etoposide alone in extensive-stage small cell lung cancer
MOH_2017-04-18_000319Phase 3Recruiting
- Sponsor
- AstraZeneca
- Start
- Feb 2017
- Modality
- Small Molecules, DNA Intercalators/Alkylators → Nucleic Acid-Directed Small Molecules → Small Molecules, Classical Binding Small Molecules → Small Molecules
- Countries
- 1
01
Overview
Phase 3, randomised, open-label trial of durvalumab, tremelimumab, etoposide, carboplatin and cisplatin in small cell lung cancer (SCLC) (3 arms), sponsored by AstraZeneca. Started Feb 2017; status: recruiting.
02
Drugs
durvalumabtremelimumabetoposidecarboplatincisplatin
03
Conditions
small cell lung cancer (SCLC)
Beyond the preview
Go deeper on MOH_2017-04-18_000319.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on MOH_2017-04-18_000319.